Resources
5:44
Top 3 questions – Chronic Conditions
Hear Doctor Lucas De Toca, COVID-19 Primary Care Response First Assistant Secretary, talk about chronic illness.
00:06:33
Top 3 questions – Men's Health Week with Dr Lucas de Toca (Part 1)
Hear from Dr Lucas de Toca talk about whether men are more susceptible to certain illnesses or conditions compared to women, and when men should start regular health checks and screening tests.
00:07:12
Top 3 questions – Men's Health Week with Dr Lucas de Toca (Part 2)
In celebration of Men’s Health Week, hear from Dr Lucas de Toca on how family history and lifestyle impact our health and learn tips to help maintain a healthy lifestyle.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 14 October 2022
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 13th meeting on 14 October 2022
Life Saving Drugs Program – Avalglucosidase alfa (Nexviazyme®) outcome statement
Summary of the consideration of the application from Sanofi Pty Ltd for the inclusion of avalglucosidase alfa (Nexviazyme®) on the Life Saving Drugs Program (LSDP) for the treatment of Pompe Disease.
Elosulfase alfa Terms of Reference and Protocol Questions
This report outlines the Elosulfase alfa 24 Month Review Terms of Reference and Protocol Questions
Providing health care to a thalidomide survivor fact sheet
This fact sheet is designed to help facilitate discussions between thalidomide survivors and their health care practitioners.
Coronavirus (COVID-19) at a glance – 20 June 2022
This infographic provides a quick view of the coronavirus (COVID-19) situation in Australia on 20 June 2022
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 24 June 2022
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 12th meeting on 24 June 2022
Life Saving Drugs Program – Asfotase alfa (Strensiq®) outcome statement – 13 May 2022
This document states the outcome of Alexion Pharmaceuticals Australasia's application to include asfotase alfa on the Life Saving Drugs Program.
Evaluation of the Chronic Pain MedsCheck Trial – Final report
This report presents the results of the project to trial a pharmacist-led support service for patients who take medication to manage chronic pain.
National Site of Recognition Steering Committee communique – 20 January 2022
This communique outlines the main points from discussion from the National Site of Recognition Steering Committee meeting including the next steps in the development of the National Site of Recognition for thalidomide survivors and their families.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 18th February 2022
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 11th meeting on 18th February 2022.
National Site of Recognition Steering Committee communique – 9 December 2021
Details of the second meeting of Steering Committee for the National Site of Recognition for thalidomide survivors and their families, held on 9 December 2021.
National Site of Recognition Steering Committee communique – 1 November 2021
Details of the meeting of the National Site of Recognition for thalidomide survivors and their families Steering Committee held on 1 November 2021.
Australian National Diabetes Strategy 2021–2030
The Australian Government has developed a new national diabetes strategy. This strategy updates and prioritises the response to diabetes for all governments.
COVID-19 vaccination – vaccination data – 31 October 2021
This data file contains statistical data about Australia's COVID-19 vaccinations.
National Health Reform Agreement (NHRA) – Long-term health reforms roadmap
This reform roadmap outlines how the Australian Government and state and territory governments will work together to improve health outcomes for all Australians and ensure our health system is sustainable.
National Strategic Action Plan for Heart Disease and Stroke
The National Strategic Action Plan for Heart Disease and Stroke provides a roadmap to achieve a healthier Australia by tackling heart disease and stroke, two of the nation’s biggest killers.
Life Saving Drugs Program (LSDP) Expert Panel meeting agenda – 8th October 2021
Life Saving Drugs Program Expert Panel (LSDPEP) agenda for the 10th meeting on 8th October 2021.
Cerliponase alfa terms of reference and protocol questions
This report outlines the Cerliponase alfa 24 month review terms of reference and protocol questions
Migalastat terms of reference and protocol questions
This report outlines the Migalastat 24 month review terms of reference and protocol questions.
Australian Government response to National Rural Health Commissioner’s report on improving the access, quality and distribution of allied health services in rural and remote Australia
This is the Australian Government response to the former Commissioner, Emeritus Professor Paul Worley’s report. The response outlines the work that will be undertaken to improve the capacity, quality, and distribution of allied health services to meet the needs of rural and remote Australians.
Rare Diseases – Support, Education and Training Grant Opportunity GO2815
Rare Diseases – Support, Education and Training Grant Opportunity general feedback for the information of grant applicants.
Heart Disease and Stroke – Early Detection
This document provides general feedback on the Grant Opportunity for Heart Disease and Stroke – Early Detection GO2796 for the information of grant applicants.
Date last updated: